Novelstem International Corp. (NSTM) — SEC Filings
Novelstem International Corp. (NSTM) — 9 SEC filings. Latest: 10-Q (Nov 12, 2025). Includes 6 10-Q, 2 10-K, 1 8-K.
View Novelstem International Corp. on SEC EDGAR
Overview
Novelstem International Corp. (NSTM) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 12, 2025: NovelStem International Corp. (NSTM) reported a significant turnaround in net income for the nine months ended September 30, 2025, achieving a net income of $2,469,177, a substantial improvement from a net loss of $3,070,027 in the prior year period. This positive shift was primarily driven by a $1,
Sentiment Summary
Across 9 filings, the sentiment breakdown is: 2 bearish, 7 neutral. The dominant filing sentiment for Novelstem International Corp. is neutral.
Filing Type Overview
Novelstem International Corp. (NSTM) has filed 6 10-Q, 2 10-K, 1 8-K with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (9)
| Date | Form | Description | Risk |
|---|---|---|---|
| Nov 12, 2025 | 10-Q | NovelStem Swings to Profit on Debt Relief, Asset Sales; Cash Dwindles | high |
| Aug 6, 2025 | 10-Q | NovelStem's Losses Widen 67% Amid Zero Revenue | high |
| May 19, 2025 | 10-Q | NovelStem International Corp. Files Q1 2025 10-Q | low |
| Apr 7, 2025 | 10-K | NovelStem International Corp. Files 2024 Annual Report | low |
| Nov 14, 2024 | 10-Q | NovelStem International Corp. Files Q3 2024 10-Q | low |
| Aug 14, 2024 | 10-Q | 10-Q Filing | |
| May 15, 2024 | 10-Q | NovelStem International Corp. Files 10-Q for Period Ending March 31, 2024 | |
| Apr 1, 2024 | 10-K | NovelStem International Corp. Files 2023 Annual Report on Form 10-K | low |
| Jan 23, 2024 | 8-K | NovelStem Changes Certifying Accountant on Jan 23 |
Risk Profile
Risk Assessment: Of NSTM's 6 recent filings, 2 were flagged as high-risk, 0 as medium-risk, and 4 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | N/A |
| Net Income | $2,469,177 |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $627 |
| Operating Margin | N/A |
| Total Assets | $14,849 |
| Total Debt | $2,067,209 |
Industry Context
NovelStem International Corp. operates in a highly competitive and capital-intensive biotechnology sector. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. Companies often rely on substantial funding rounds or strategic partnerships to advance their pipelines. Recent trends show increased consolidation and a focus on specialized therapeutic areas.
Top Tags
10-Q (4) · SEC Filing (3) · quarterly-report (2) · 10-K (2) · NovelStem International Corp. (2) · Going Concern (1) · Biotech (1) · Holding Company (1) · Debt Restructuring (1) · Asset Sales (1)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net income | $2,469,177 | for the nine months ended September 30, 2025, a significant improvement from a $3,070,027 net loss in 2024 |
| Cash | $627 | as of September 30, 2025, down from $6,099 at December 31, 2024 |
| Relief of indebtedness income | $1,697,024 | a primary driver of net income for the nine months ended September 30, 2025 |
| Gain on disposal of equity method investment | $1,171,760 | contributed to net income for the nine months ended September 30, 2025 |
| Accumulated deficit | $294,000,000 | as of September 30, 2025, indicating long-term unprofitability |
| Total assets | $14,849 | as of September 30, 2025, a sharp decline from $160,111 at December 31, 2024 |
| Total liabilities | $2,067,209 | as of September 30, 2025, reduced from $5,304,486 at December 31, 2024 |
| General and administrative expenses | $198,007 | for the nine months ended September 30, 2025, a decrease from $893,887 in the prior year |
| Common Stock Shares Outstanding | 46,881,475 | as of November 12, 2025 |
| Revenue | $0 | No revenue generated for the six months ended June 30, 2025, or 2024. |
| Net Loss | $1.25M | Net loss for the six months ended June 30, 2025, increased by 66.7% from $750,000 in 2024. |
| Loss Increase | 66.7% | Percentage increase in net loss from the prior year period. |
| Cash Decrease | $500K | Reduction in cash position from December 31, 2024, to June 30, 2025. |
| Reporting Period End Date | 20250331 | Indicates the end of the financial quarter being reported. |
| Filing Date | 20250519 | The date the 10-Q was officially submitted to the SEC. |
Frequently Asked Questions
What are the latest SEC filings for Novelstem International Corp. (NSTM)?
Novelstem International Corp. has 9 recent SEC filings from Jan 2024 to Nov 2025, including 6 10-Q, 2 10-K, 1 8-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of NSTM filings?
Across 9 filings, the sentiment breakdown is: 2 bearish, 7 neutral. The dominant sentiment is neutral.
Where can I find Novelstem International Corp. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Novelstem International Corp. (NSTM) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Novelstem International Corp.?
Key financial highlights from Novelstem International Corp.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for NSTM?
The investment thesis for NSTM includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Novelstem International Corp.?
Executive information for Novelstem International Corp. is extracted from SEC filings as they are enriched with AI analysis.
What are the main risk factors for Novelstem International Corp. stock?
Of NSTM's 6 assessed filings, 2 were flagged high-risk, 0 medium-risk, and 4 low-risk.
What are recent predictions and forward guidance from Novelstem International Corp.?
Forward guidance and predictions for Novelstem International Corp. are extracted from SEC filings as they are enriched.